| 101 |
31371779 | Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence. | 2019 Sep |
2 |
| 102 |
31372066 | Novel approaches to treating advanced systemic mastocytosis. | 2019 |
1 |
| 103 |
31471313 | Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. | 2019 Dec 15 |
1 |
| 104 |
32053767 | Precision medicine in gastrointestinal stromal tumors. | 2019 Nov-Dec |
1 |
| 105 |
27384439 | Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor. | 2018 Mar |
1 |
| 106 |
28710566 | Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline KIT-Trp557Arg mutation: case report and literature overview. | 2018 Apr |
3 |
| 107 |
28736245 | Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases. | 2018 Apr |
1 |
| 108 |
29143894 | Mechanism of Resistance in Gastrointestinal Stromal Tumors. | 2018 |
1 |
| 109 |
29334307 | Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model. | 2018 |
1 |
| 110 |
29423012 | CCDC26 knockdown enhances resistance of gastrointestinal stromal tumor cells to imatinib by interacting with c-KIT. | 2018 |
4 |
| 111 |
29439183 | The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. | 2018 May |
1 |
| 112 |
29494307 | Recurrent Spindle Cell Carcinoma Shows Features of Mesenchymal Stem Cells. | 2018 Jul |
1 |
| 113 |
29523662 | A Novel PRKAR1B-BRAF Fusion in Gastrointestinal Stromal Tumor Guides Adjuvant Treatment Decision-Making During Pregnancy. | 2018 Mar |
1 |
| 114 |
29552659 | Management of rectal gastrointestinal stromal tumor. | 2018 |
2 |
| 115 |
29600692 | The window of opportunities for targeted therapy in BRAFwt/NRASwt/KITwt melanoma: biology and clinical implications of fusion proteins and other mutations. | 2018 Jun |
1 |
| 116 |
29620139 | Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression. | 2018 Jul |
5 |
| 117 |
29623544 | SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling. | 2018 Nov |
1 |
| 118 |
29682621 | Surgery for metastatic gastrointestinal stromal tumor: to whom and how to? | 2018 |
1 |
| 119 |
29704617 | The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders. | 2018 Jul |
2 |
| 120 |
29724653 | A naphthalene diimide G-quadruplex ligand inhibits cell growth and down-regulates BCL-2 expression in an imatinib-resistant gastrointestinal cancer cell line. | 2018 Jul 15 |
2 |
| 121 |
29764854 | Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors. | 2018 Sep 1 |
2 |
| 122 |
29969914 | Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor. | 2018 Jul |
1 |
| 123 |
29998023 | Gastrointestinal stromal tumours: advances in surgical and pharmacological management options. | 2018 Jun |
1 |
| 124 |
30007460 | Kit Mutations: New Insights and Diagnostic Value. | 2018 Aug |
1 |
| 125 |
30069623 | Imatinib Mesylate. | 2018 |
1 |
| 126 |
30101284 | Translational insights into gastrointestinal stromal tumor and current clinical advances. | 2018 Oct 1 |
1 |
| 127 |
30159192 | Adult Intussusception due to Gastrointestinal Stromal Tumor: A Rare Case Report, Comprehensive Literature Review, and Diagnostic Challenges in Low-Resource Countries. | 2018 |
2 |
| 128 |
30224936 | Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review. | 2018 |
1 |
| 129 |
30253992 | Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype. | 2018 Dec |
1 |
| 130 |
30268485 | Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848 K mutation. | 2018 Oct |
1 |
| 131 |
30286478 | Cell-Free DNA and Neuromediators in Detecting Aggressive Variant Prostate Cancer. | 2018 |
1 |
| 132 |
30298093 | (+)-Usnic Acid Inhibits Migration of c-KIT Positive Cells in Human Colorectal Cancer. | 2018 |
1 |
| 133 |
30311036 | A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β. | 2018 Dec |
2 |
| 134 |
30396237 | Inhibition of MicroRNA-221 and 222 Enhances Hematopoietic Differentiation from Human Pluripotent Stem Cells via c-KIT Upregulation. | 2018 Nov 30 |
1 |
| 135 |
30396570 | Imatinib mesylate elicits extracellular signal-related kinase (ERK) activation and enhances the survival of γ-irradiated epithelial cells. | 2018 Dec 2 |
1 |
| 136 |
30488756 | Activated tyrosine kinases in gastrointestinal stromal tumor with loss of KIT oncoprotein expression. | 2018 |
2 |
| 137 |
30500954 | Interplay between transcription regulators RUNX1 and FUBP1 activates an enhancer of the oncogene c-KIT and amplifies cell proliferation. | 2018 Nov 30 |
2 |
| 138 |
30545989 | Pathologic Complete Response in a Large Gastric GIST: Using Molecular Markers to Achieve Maximal Response to Neoadjuvant Imatinib. | 2018 Dec |
1 |
| 139 |
30567202 | Imatinib and liver toxicity. | 2018 Dec 7 |
2 |
| 140 |
27470968 | PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. | 2017 Jan 15 |
1 |
| 141 |
27687311 | Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma. | 2017 Jan 1 |
2 |
| 142 |
27965460 | Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate. | 2017 Jan 17 |
4 |
| 143 |
27997714 | Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors. | 2017 Apr |
2 |
| 144 |
28074523 | Familial gastrointestinal stromal tumors, lentigines, and café-au-lait macules associated with germline c-kit mutation treated with imatinib. | 2017 Feb |
1 |
| 145 |
28192400 | Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors. | 2017 Jun 29 |
6 |
| 146 |
28196207 | Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. | 2017 Jul 1 |
2 |
| 147 |
28260860 | Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes. | 2017 |
2 |
| 148 |
28334365 | Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial. | 2017 May 1 |
2 |
| 149 |
28334439 | A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). | 2017 Jul 15 |
5 |
| 150 |
28403213 | M-COPA suppresses endolysosomal Kit-Akt oncogenic signalling through inhibiting the secretory pathway in neoplastic mast cells. | 2017 |
6 |